Vactosertib (Not yet branded)
Other Medications
Description
Vactosertib is a small molecule inhibitor of transforming growth factor beta (TGF- ) receptor I that blocks TGF-? signaling pathways. In colorectal cancer treatment, it is being combined with natural killer (NK) cell therapy and interleukin-2 to enhance immune system function against tumors. The drug targets the immunosuppressive effects of TGF-? that often allow cancer cells to evade immune detection and destruction.
Mechanism of Action
Vactosertib selectively inhibits TGF-? receptor I (ALK5) kinase activity, preventing the phosphorylation and activation of SMAD2 and SMAD3 transcription factors. By blocking this pathway, the drug reduces TGF- -mediated immunosuppression in the tumor microenvironment, potentially allowing enhanced NK cell and T-cell anti-tumor activity.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | Oral |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.